Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cilofexor passes phase 2 for primary biliary cholangitis

Publish date:: November 12, 2019

Key clinical point: Cilofexor, a nonsteroidal farnesoid X receptor agonist, can reduce serum levels of liver biomarkers in patients with primary biliary cholangitis (PBC).

Major finding: Patients treated with cilofexor 100 mg had a median decrease in serum ALP of 13.8%.

Study details: A phase 2 placebo-controlled trial involving 71 patients with PBC.

Disclosures: The study was funded by Gilead. The investigators disclosed additional relationships with Allergan, Novartis, GlaxoSmithKline, and others.

Citation:

Kowdley KV et al. The Liver Meeting 2019. Abstract 45.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

IBD patients prefer vedolizumab over anti-TNF drugs,

During pandemic, many gastroenterologists report low resilience, insomnia,